ATE236261T1 - Dna-expressionssysteme basierend auf alphaviren - Google Patents

Dna-expressionssysteme basierend auf alphaviren

Info

Publication number
ATE236261T1
ATE236261T1 AT92900560T AT92900560T ATE236261T1 AT E236261 T1 ATE236261 T1 AT E236261T1 AT 92900560 T AT92900560 T AT 92900560T AT 92900560 T AT92900560 T AT 92900560T AT E236261 T1 ATE236261 T1 AT E236261T1
Authority
AT
Austria
Prior art keywords
alphaviruses
expression systems
systems based
dna expression
recombinant
Prior art date
Application number
AT92900560T
Other languages
English (en)
Inventor
Henrik Garoff
Peter Liljestroem
Original Assignee
Bioption Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20381182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE236261(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption Ab filed Critical Bioption Ab
Application granted granted Critical
Publication of ATE236261T1 publication Critical patent/ATE236261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT92900560T 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren ATE236261T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003978A SE9003978D0 (sv) 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon
PCT/SE1991/000855 WO1992010578A1 (en) 1990-12-13 1991-12-12 Dna expression systems based on alphaviruses

Publications (1)

Publication Number Publication Date
ATE236261T1 true ATE236261T1 (de) 2003-04-15

Family

ID=20381182

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900560T ATE236261T1 (de) 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren

Country Status (12)

Country Link
US (3) US5739026A (de)
EP (1) EP0561890B1 (de)
JP (2) JP3435511B2 (de)
AT (1) ATE236261T1 (de)
AU (1) AU656545B2 (de)
CA (2) CA2098292A1 (de)
DE (1) DE69133228T2 (de)
DK (1) DK0561890T3 (de)
ES (1) ES2195998T3 (de)
FI (1) FI932678L (de)
SE (1) SE9003978D0 (de)
WO (1) WO1992010578A1 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
CA2158937C (en) * 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Recombinant alphavirus vectors
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) * 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US6489167B1 (en) 1996-09-25 2002-12-03 The Government Of The United States As Represented By The Secretary Of The Department Of Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
CA2268353A1 (en) * 1996-10-10 1998-04-16 Henrik Garoff Alphavirus-retrovirus vectors
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
ATE374247T1 (de) 1997-10-14 2007-10-15 Darwin Molecular Corp Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
WO1999025858A1 (en) 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
AU754320B2 (en) 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
WO1999058639A2 (en) * 1998-05-08 1999-11-18 Akzo Nobel N.V. Structural proteins of fish pancreatic disease virus and uses thereof
EP1953229A3 (de) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatische Brust- und Dickdarmkrebs-regulierte Gene
DK1135162T3 (da) * 1998-11-30 2009-01-19 Cytos Biotechnology Ag Ordnet molekylær præsentation af allergener, fremstillingsfremgangsmåde samt anvendelse
PT1141331E (pt) 1998-12-16 2008-12-22 Novartis Vaccines & Diagnostic Quinase dependente de ciclina humana (hpnqalre)
AU4366000A (en) * 1999-04-14 2000-11-14 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US8647864B2 (en) * 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6297013B1 (en) 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
CN1413258A (zh) 1999-10-26 2003-04-23 国际艾滋病疫苗行动组织 用于表达甲病毒复制子的侵袭性细菌载体
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
JP2003531583A (ja) 2000-03-08 2003-10-28 カイロン コーポレイション ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1741782B1 (de) * 2000-05-10 2011-06-22 Sanofi Pasteur Limited Durch Mage Minigene kodierte immunogene Polypeptide und ihre Verwendungen
CA2410948C (en) * 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001290642A1 (en) * 2000-09-07 2002-03-22 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
DE60141533D1 (de) 2000-12-08 2010-04-22 Life Technologies Corp Ukleinsäuremolekülen unter verwendung multipler erkennungsstellen
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CA2440890C (en) * 2001-03-27 2011-07-19 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
ES2356934T3 (es) 2001-06-05 2011-04-14 Curevac Gmbh ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL.
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
KR100981471B1 (ko) 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의ｐ4 변형 단백질
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
ATE489969T1 (de) * 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
WO2004007538A2 (en) * 2002-07-17 2004-01-22 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
MXPA04012010A (es) * 2002-07-18 2005-03-07 Cytos Biotechnology Ag Conjugados de hapteno-portador que comprende particulas similares a virus, y usos de los mismos.
DK1524994T3 (da) 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
JP2006503914A (ja) 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
EP3246399B1 (de) 2002-12-13 2021-07-07 Alphavax, Inc. Alphavirus-partikel und methoden für ihre herstellung
WO2004055166A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
EP1608762B1 (de) 2003-03-20 2014-01-08 Alphavax, Inc. Verbesserte alphavirus replikons und helferkonstrukt
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1623229A2 (de) * 2003-05-15 2006-02-08 Cytos Biotechnology AG Selektion von b-zellen mit gewünschter spezifität: verfahren zur herstellung und deren verwendung
US7419674B2 (en) 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
JP2007518762A (ja) * 2004-01-20 2007-07-12 サイトス バイオテクノロジー アーゲー グレリン−担体結合体
CA2561696C (en) 2004-03-29 2013-09-03 Galpharma Co., Ltd. Novel modified galectin 9 proteins and use thereof
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
AU2005249218A1 (en) * 2004-06-02 2005-12-15 Cytos Biotechnology Ag Medical uses of carrier conjugates of non-human TNF-peptides
WO2005122675A2 (en) * 2004-06-21 2005-12-29 Quattromed As Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proetins
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2008085557A2 (en) 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
WO2008033966A2 (en) 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
EP2099485B1 (de) * 2006-11-03 2018-03-21 AlphaVax, Inc. Zusammensetzungen aus alphaviren oder alphavirus replikon partikeln und dazugehörende methoden
EP2139447A2 (de) 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
JP5602624B2 (ja) 2007-06-21 2014-10-08 アルファバックス， インコーポレイテッド αウイルス構造タンパク質の発現のためのプロモーターレスカセット
RU2506275C2 (ru) 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
EP2370584B1 (de) 2008-12-01 2014-11-05 Alphavax, Inc. Verwendung von mikro-RNS zur Kontrolle von Virus Helfernukleinsäuren
ES2540958T3 (es) 2009-04-08 2015-07-15 Alphavax, Inc. Partículas de replicón de alfavirus que expresan TRP2
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EE05711B1 (et) 2009-10-07 2014-04-15 Tartu Ülikool Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
EP2663868A2 (de) 2010-12-01 2013-11-20 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen zur abzielung auf neovaskuläre wachstumsstellen
EP2668201A2 (de) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2017184456A1 (en) * 2016-04-18 2017-10-26 Rima Mcleod Toxoplasma gondii vaccines and their use
HUE059594T2 (hu) * 2017-02-27 2022-11-28 Translate Bio Inc Hírvivõ RNS tisztítására szolgáló eljárások
EP4010350A4 (de) 2019-08-09 2023-11-22 Nutcracker Therapeutics, Inc. Verfahren und vorrichtungen zur herstellung für die entfernung von material aus einer therapeutischen zusammensetzung
IL321887A (en) 2023-01-12 2025-09-01 Bavarian Nordic As Recombinantly modified Sarna (vrp) for cancer vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288073C (en) * 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems

Also Published As

Publication number Publication date
AU9078791A (en) 1992-07-08
CA2614365A1 (en) 1992-06-25
WO1992010578A1 (en) 1992-06-25
SE9003978D0 (sv) 1990-12-13
DE69133228T2 (de) 2003-10-30
EP0561890B1 (de) 2003-04-02
CA2098292A1 (en) 1992-06-14
DE69133228D1 (de) 2003-05-08
US20020151067A1 (en) 2002-10-17
EP0561890A1 (de) 1993-09-29
JP2003159085A (ja) 2003-06-03
AU656545B2 (en) 1995-02-09
FI932678A7 (fi) 1993-07-27
FI932678A0 (fi) 1993-06-11
JP3435511B2 (ja) 2003-08-11
JP4018479B2 (ja) 2007-12-05
US5739026A (en) 1998-04-14
JPH06504198A (ja) 1994-05-19
ES2195998T3 (es) 2003-12-16
FI932678L (fi) 1993-07-27
DK0561890T3 (da) 2003-07-21
US6190666B1 (en) 2001-02-20

Similar Documents

Publication Publication Date Title
ATE236261T1 (de) Dna-expressionssysteme basierend auf alphaviren
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
ATE184052T1 (de) Gdf-1 und uog1 proteine
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DK0757717T3 (da) Papillomavirusvacciner
MY102472A (en) Preparation of funtional human urokinase proteins.
DE3888086D1 (de) Rekombinantes Geflügelpockenvirus, Expressionsvektoren für heterologische Proteine und davon derivierte Geflügelvakzine.
DK251890D0 (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
YU150891A (sh) Rekombinantna genetska informacija
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
AR011740A1 (es) Proteinas del virus que produce enrollamiento en las hojas de la vid del tipo 2, secuencias de codificacion y metodos
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
NO950420D0 (no) Interferon endelse derav
BR0010222A (pt) Vetores de expressão viral
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
SE8100581L (sv) Gen och underenhet till densamma, plastmidvektor innehallande denna gen eller ungerenhet, forfarande for genens, underenhetens och vektorns framstellning och anvendning samt salunda erhallna celler och interferonlikn...
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
DE60026666D1 (de) Induktion von antigen-spezifischen T-Zellen durch Interferon
KR830010193A (ko) 바실러스 클로닝 매개체, 재결합 dna분자 그것들과 함께 변형된 간균 숙주 그리고 이종(異知) dna배열의 표현 방법과 그것으로 이루어진 폴리펩타이드의 생성방법
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0561890

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked